Comparison of clinical features in the BM−, BM+, concordant BM+, and discordant BM+ groups
| Clinical features . | BM−, n = 434 . | BM+, n = 55 . | Concordant BM involvement, n = 29 . | Discordant BM involvement, n = 26 . |
|---|---|---|---|---|
| Sex | ||||
| Male, no. (%) | 231 (53.2) | 25 (45.5) | 11 (37.9) | 14 (53.8) |
| Female, no. | 203 | 30 | 18 | 12 |
| Age | ||||
| 60 y and younger, no. (%) | 183 (42.2) | 19 (34.5) | 6 (20.7)* | 13 (50)† |
| Older than 60 y, no. | 251 | 36 | 23 | 13 |
| Stage | ||||
| 1-2, no. (%) | 261 (60.1) | 0 (0)‡ | 0 (0)* | 0 (0) |
| 3-4, no. | 173 | 55 | 29 | 26 |
| Stage, excluding BM status | ||||
| 1-2, no. (%) | 261 (60.1) | 38 (69.1) | 19 (65.5) | 19 (73.1) |
| 3-4, no. | 173 | 17 | 10 | 7 |
| Extranodal sites | ||||
| 0-1, no. (%) | 386 (88.9) | 33 (60.0)‡ | 16 (55.2)* | 17 (65.4) |
| 2 or more, no. | 48 | 22 | 13 | 9 |
| Extranodal sites, excluding BM | ||||
| 0-1, no. (%) | 386 (88.9) | 51 (92.7) | 25 (86.2) | 26 (100) |
| 2 or more, no. | 48 | 4 | 4 | 0 |
| LDH | ||||
| Normal, no. (%) | 219 (50.5) | 19 (34.5)‡ | 6 (20.7)* | 13 (50)† |
| Elevated, no. | 215 | 36 | 23 | 13 |
| ECOG score | ||||
| 0-1, no. (%) | 380 (87.6) | 45 (81.8) | 22 (75.9) | 23 (88.5) |
| 2-4, no. | 54 | 10 | 7 | 3 |
| IPI score, no. (%) | ||||
| Low (0-1) | 203 (46.8) | 2 (3.6) | 0 (0) | 2 (7.7) |
| Intermediate (2-3) | 198 (45.6) | 41 (74.5) | 20 (70.0) | 21 (80.8) |
| High (4-5) | 33 (7.6) | 12 (21.8)‡§ | 9 (31.0)*§ | 3 (11.5)†§ |
| Clinical features . | BM−, n = 434 . | BM+, n = 55 . | Concordant BM involvement, n = 29 . | Discordant BM involvement, n = 26 . |
|---|---|---|---|---|
| Sex | ||||
| Male, no. (%) | 231 (53.2) | 25 (45.5) | 11 (37.9) | 14 (53.8) |
| Female, no. | 203 | 30 | 18 | 12 |
| Age | ||||
| 60 y and younger, no. (%) | 183 (42.2) | 19 (34.5) | 6 (20.7)* | 13 (50)† |
| Older than 60 y, no. | 251 | 36 | 23 | 13 |
| Stage | ||||
| 1-2, no. (%) | 261 (60.1) | 0 (0)‡ | 0 (0)* | 0 (0) |
| 3-4, no. | 173 | 55 | 29 | 26 |
| Stage, excluding BM status | ||||
| 1-2, no. (%) | 261 (60.1) | 38 (69.1) | 19 (65.5) | 19 (73.1) |
| 3-4, no. | 173 | 17 | 10 | 7 |
| Extranodal sites | ||||
| 0-1, no. (%) | 386 (88.9) | 33 (60.0)‡ | 16 (55.2)* | 17 (65.4) |
| 2 or more, no. | 48 | 22 | 13 | 9 |
| Extranodal sites, excluding BM | ||||
| 0-1, no. (%) | 386 (88.9) | 51 (92.7) | 25 (86.2) | 26 (100) |
| 2 or more, no. | 48 | 4 | 4 | 0 |
| LDH | ||||
| Normal, no. (%) | 219 (50.5) | 19 (34.5)‡ | 6 (20.7)* | 13 (50)† |
| Elevated, no. | 215 | 36 | 23 | 13 |
| ECOG score | ||||
| 0-1, no. (%) | 380 (87.6) | 45 (81.8) | 22 (75.9) | 23 (88.5) |
| 2-4, no. | 54 | 10 | 7 | 3 |
| IPI score, no. (%) | ||||
| Low (0-1) | 203 (46.8) | 2 (3.6) | 0 (0) | 2 (7.7) |
| Intermediate (2-3) | 198 (45.6) | 41 (74.5) | 20 (70.0) | 21 (80.8) |
| High (4-5) | 33 (7.6) | 12 (21.8)‡§ | 9 (31.0)*§ | 3 (11.5)†§ |
Statistically significant difference between concordant BM and BM-negative groups (P < .05).
Statistically significant difference between discordant BM and concordant BM groups (P < .05).
Statistically significant difference between BM-positive and BM-negative groups (P < .05).
Significant differences between 2 groups regarding IPI status were determined using 3 × 2 tables and the chi-squared test.